Novel approach may protect against heart attack injury

July 11, 2008

Drugs target gene pathways to preserve heart, possibly other organs

Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects.

"Reduced blood flow, or ischemia, is a major problem in many organs, where it can lead to cell death and tissue damage," said study leader Peter J. Gruber, M.D., Ph.D., a cardiothoracic surgeon at Children's Hospital and a faculty member of the University of Pennsylvania School of Medicine. "We decided to look for a global approach to protecting heart tissue by inhibiting enzymes that govern how cells respond to ischemia."

Gruber's team published their findings online July 7 in the journal of the Federation of American Societies for Experimental Biology (FASEB). The article will appear in the journal's October 2008 print issue.

The researchers made use of drugs called histone deactylase (HDAC) inhibitors that alter the way DNA is packaged within cells, as well as modifying the function of other proteins. Building on previous work by other researchers, who showed that HDAC inhibitors reduce ischemic injury in the brain, they used the same agents in mice with induced heart damage.

"We found significant and dramatic results in the mice," said Gruber. "The HDAC inhibitors reduced the area of tissue injury, even when delivered an hour after the ischemic event occurred." The size of the myocardial infarction-an area of dead tissue caused by obstructed blood flow, as occurs after a heart attack-was reduced by more than half.

In further investigating how the HDAC inhibitors acted, Gruber's team found they blocked gene pathways that led to cell death and ischemia-induced vascular permeability, the leakage of fluid through blood vessels. They also identified a specific molecule, HDAC4, as the likely HDAC enzyme with the most critical role in affecting how cells respond to ischemia.

An important advantage of their finding, said Gruber, is that a number of HDAC inhibitors are already used in medicine, for treating both cancer and epilepsy, and are well-tolerated. Although much research remains to be done, he added, this raises the possibility that existing drugs, or modified versions of them, might play an important new role in heart disease.

Because the protective effect of HDAC inhibitors may occur even after the initial blockage of blood flow, therapies based on Gruber's research may lead to an emergency treatment following a heart attack. In addition, because open-heart surgery for both children and adults requires a period in which the heart is stopped, such treatment might also protect tissues from the adverse effects of interrupting blood flow during surgery.

For now, said Gruber, the next step for his study team will be to test how HDAC inhibitors work in protecting against ischemic injury in larger animals.

Children's Hospital of Philadelphia

---

---

	CuraGen and TopoTarget sign collaboration agreement for development and commercialization of Phase I HDAC inhibitor for oncology.: An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2004. The length of the article is 1409 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: CuraGen and TopoTarget sign collaboration agreement for development and commercialization of Phase I HDAC inhibitor for oncology. Publication: BIOTECH Patent News (Newsletter) Date: May 1, 2004 Publisher: Biotech Patent News Volume: 18 Issue: 5 Distributed by Thomson...
	Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis.(Hypothesis): An article from: Bioinformation by Kalyanamoorthy Subha (Author), Gopal Ramesh Kumar (Author) This digital document is an article from Bioinformation, published by Biomedical Informatics Publishing Group on January 1, 2008. The length of the article is 2339 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. From the author: Abbreviations: HDAC = histone deacetylase, HDACi = histone deacetylase inhibitor, TPSA = total polar surface area, SCR = structurally conserved region. Citation Details Title: Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis.(Hypothesis) Author: Kalyanamoorthy Subha Publication: Bioinformation (Magazine/Journal) Date:...
	Competitor Analysis: HDAC Inhibitors by La Merie Publishing (Author) The present Competitive Intelligence report about HDAC Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting histone deacetylase for treatment of cancer and other diseases as of July 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor and normal tissues, providing a...
	Histone Deacetylases: the Biology and Clinical Implication (Handbook of Experimental Pharmacology) by Tso-Pang Yao (Editor), Edward Seto (Editor) The book highlights work from many different labs that taught us abnormal HDACs potentially contribute to the development or progression of many human diseases including immune dysfunctions, heart disease, cancer, memory impairment, aging, and metabolic disorders.
	The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance by Nessa Carey (Author) Epigenetics can potentially revolutionize our understanding of the structure and behavior of biological life on Earth. It explains why mapping an organism's genetic code is not enough to determine how it develops or acts and shows how nurture combines with nature to engineer biological diversity. Surveying the twenty-year history of the field while also highlighting its latest findings and innovations, this volume provides a readily understandable introduction to the foundations of epigenetics.Nessa Carey, a leading epigenetics researcher, connects the field's arguments to such diverse phenomena as how ants and queen bees control their colonies; why tortoiseshell cats are always female; why some plants need cold weather before they can flower; and how our bodies age and develop disease....
	Pathophysiology: The Biologic Basis for Disease in Adults and Children, 6e by Kathryn L. McCance (Editor), Sue E. Huether (Editor) Well-known for its authoritative and comprehensive coverage, complete treatment of pediatric pathophysiology, and the most extensive illustration program in its field, this textbook features expert content on everything from the general principles of pathophysiology to detailed discussions of genetics and specific diseases. Chapters on alteration present the pathophysiology, clinical manifestations, and evaluation and treatment of each disease to help you learn to identify normal anatomy and physiology, as well as alterations of function in adults and in children.Unparalleled coverage of disease processes makes this text the most comprehensive pathophysiology text available. The largest full-color art program in the field illustrates the clinical manifestations of diseases and disease...
	Adult Acute Lymphocytic Leukemia: Biology and Treatment (Contemporary Hematology) by Anjali S. Advani (Editor), Hillard M. Lazarus (Editor) The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular...
	Understanding Pathophysiology, 5e (Huether, Understanding Pathophysiology) by Sue E. Huether RN PhD (Author), Kathryn L. McCance RN PhD (Author) Learn the essential concepts of pathophysiology and stay up to date on treatments, manifestations, and mechanisms of disease with Understanding Pathophysiology, 5th Edition. Filled with vibrant illustrations and complemented by online resources that bring pathophysiology concepts to life, this easy-to-read text delivers the latest, most accurate information on the disease process across the lifespan, giving you the fundamental knowledge you need to move forward in your nursing education. Consistent presentation helps you better distinguish pathophysiology, clinical manifestations, and evaluation and treatment for each disease.More than 1,000 high-quality illustrations vividly depict clinical manifestations and cellular mechanisms underlying diseases.Lifespan coverage details age-specific...
	Bortezomib in the Treatment of Multiple Myeloma (Milestones in Drug Therapy) by Irene M. Ghobrial (Editor), Paul G. Richardson (Editor), Kenneth C. Anderson (Editor) Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of...
	Small Molecules in Oncology (Recent Results in Cancer Research) by Uwe M. Martens (Editor) Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.